Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX009 Safety and PK/PD in Healthy Volunteers
NCT04535752Phase 1Completed
- Sponsor
- Annexon Biosciences
- Start
- Oct 2020
- Primary completion
- Jun 2021
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ANX009 in systemic lupus erythematosus (SLE) (4 arms), sponsored by Annexon Biosciences. Primary endpoint: Number of Participants Who Experienced Treatment-Emergent Adverse Events. Started Oct 2020; status: completed.
02
Drugs
ANX009
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04535752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535752.